Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Jifeng Feng et al.|The Lancet Respiratory Medicine|2020Cited by 504
Expert consensus on treatment for stage III non‐small cell lung cancerYi‐Long Wu, Yun Fan, Shun Lü et al.|Medicine Advances|2023Cited by 18
Treatment‐Related Adverse Events of Antibody‐Drug Conjugate Monotherapy in Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐AnalysisYun Fan, Linjing Zhou, Sini Li et al.|Thoracic Cancer|2025Cited by 3